71 results on '"Rocci, Alberto"'
Search Results
2. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
3. RWD-derived response in multiple myeloma
4. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
5. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
6. Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database
7. Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial
8. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
9. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
10. Evaluating Suspected Cardiac Amyloidosis
11. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
12. Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations
13. TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
14. High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma
15. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
16. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
17. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
18. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
19. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers
20. Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers
21. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
22. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
23. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix
24. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
25. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
26. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
27. Abstract 4855: Proteomic characterization of the extracellular matrix in multiple myeloma
28. The potential of miRNAs as biomarkers for multiple myeloma
29. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
30. Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
31. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors
32. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma
33. A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
34. Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation
35. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
36. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
37. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
38. Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation.
39. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
40. High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma
41. MiR-221 and MiR-222 Patterns Characterize Burkitt Lymphoma in Human and Mouse Model
42. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.
43. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment
44. Abstract 5032: New insights of miR-221 and miR-222 cluster functions in Burkitt lymphoma.
45. LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL
46. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations
47. Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.
48. High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease
49. A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients
50. IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.